Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 14 |
| List of Tables | 7 | 4 |
| List of Figures | 11 | 6 |
| Pain Management Therapeutics Market - Introduction | 17 | 2 |
| GBI Research Report Guidance | 18 | 1 |
| Pain Management Therapeutics Market - Market Overview | 19 | 20 |
| Introduction | 19 | 2 |
| WHO (World Health Organization) Pain Ladder | 21 | 1 |
| Risk Evaluation and Mitigation Strategy (REMS) | 22 | 1 |
| Revenue | 23 | 1 |
| Major Marketed Pain Management Drugs | 24 | 1 |
| Lyrica (pregabalin) | 25 | 1 |
| Overview | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| Efficacy | 25 | 1 |
| Safety | 26 | 1 |
| Cymbalta (duloxetine) | 26 | 1 |
| Overview | 26 | 1 |
| Efficacy | 26 | 1 |
| Safety | 26 | 1 |
| Celebrex (celecoxib) | 26 | 1 |
| Efficacy | 27 | 1 |
| Safety | 27 | 1 |
| Voltaren Gel (diclofenac sodium) | 27 | 1 |
| Overview | 27 | 1 |
| Efficacy | 27 | 1 |
| Safety | 27 | 1 |
| Imitrex(sumatriptan succinate) | 27 | 1 |
| Overview | 27 | 1 |
| Savella (milnacipran hydrochloride) | 28 | 1 |
| Overview | 28 | 1 |
| Lidoderm (lidocaine patch) | 28 | 1 |
| Overview | 28 | 1 |
| Qutenza (capsaicin) | 28 | 1 |
| Overview | 28 | 1 |
| Zomig (zolmitriptan) | 29 | 1 |
| Overview | 29 | 1 |
| Maxalt (rizatriptan benzoate) | 29 | 1 |
| Overview | 29 | 1 |
| Annual Cost of Therapy | 30 | 1 |
| Treatment Usage Patterns | 31 | 2 |
| Diseased Population | 33 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 35 | 1 |
| Prescription Population | 36 | 1 |
| Drivers and Restraints of the Pain Management Therapeutics Market | 37 | 1 |
| Drivers | 37 | 1 |
| Rising Elderly Population | 37 | 1 |
| Increased Awareness of Pain Indications | 37 | 1 |
| Strong Product Pipeline | 38 | 1 |
| Restraints | 38 | 1 |
| Pain Medications, Particularly Opioids, are Associated with Several Side Effects | 38 | 1 |
| Difficulty in Pain Diagnosis Leads to Low Prescription Rates | 38 | 1 |
| Availability of Generics | 38 | 1 |
| Pain Management Therapeutics Market - Therapeutic Landscape | 39 | 117 |
| Pain Management Therapeutics Market for Fibromyalgia | 39 | 1 |
| Introduction | 39 | 1 |
| Revenue | 40 | 1 |
| Branded vs. Generic Share | 41 | 1 |
| Annual Cost of Therapy | 42 | 1 |
| Treatment Flow Algorithm | 43 | 1 |
| Treatment Usage Patterns | 44 | 2 |
| Diseased Population | 46 | 1 |
| Treatment Seeking Population | 47 | 1 |
| Diagnosed Population | 48 | 1 |
| Prescription Population | 49 | 1 |
| Geographical Segmentation | 50 | 3 |
| Drivers and Restraints for the Fibromyalgia Market | 53 | 1 |
| FDA Approval of Lyrica, Cymbalta and Savella to Propel the Market | 53 | 1 |
| Elderly Populations will Drive Prevalence | 53 | 1 |
| Improvements in Awareness and Resultant Diagnosis Levels will Drive the Market | 53 | 1 |
| Substantial Unmet Need Increases the Market Potential | 54 | 1 |
| Restraints for the Fibromyalgia Pain Relief Market | 54 | 1 |
| Limitations in the Efficacy of Existing Drugs Can Potentially Lead to Low Prescription | 54 | 1 |
| Inadequate Knowledge of Disease Progression Hinders the Development of Drugs with Better Efficacy | 54 | 1 |
| Pain Management Therapeutics for Neuropathic Pain | 54 | 1 |
| Introduction | 54 | 1 |
| Revenue | 55 | 1 |
| Branded Vs Generic Share | 56 | 1 |
| Annual Cost of Therapy | 57 | 1 |
| Treatment Flow Algorithm | 58 | 1 |
| Treatment Usage Patterns | 59 | 1 |
| Diseased Population | 60 | 1 |
| Treatment Seeking Population | 61 | 1 |
| Diagnosed Population | 62 | 1 |
| Prescription Population | 63 | 1 |
| Geographical Segmentation | 64 | 2 |
| Drivers and Restraints for the Neuropathic Pain Market | 66 | 1 |
| Drivers | 67 | 1 |
| Ageing Populations and Increasing Prevalence of Diabetes and HIV | 67 | 1 |
| More Active Treatment Seeking Behavior to Drive Increase in Patient Volumes | 67 | 1 |
| Increased Uptake of Lyrica (pregabalin) will Drive the Neuropathic Pain Management Market | 67 | 1 |
| Restraints | 67 | 1 |
| Non-availability of Accurate Tools that Aid Diagnosis is a Hindrance for Market Growth | 67 | 1 |
| Pain Management Therapeutics Market for Migraine | 68 | 1 |
| Introduction | 68 | 1 |
| Revenue | 68 | 1 |
| Branded Vs Generic Share | 69 | 1 |
| Annual Cost of Therapy | 70 | 2 |
| Treatment Flow Algorithm | 72 | 1 |
| Treatment Usage Patterns | 73 | 2 |
| Diseased Population | 75 | 1 |
| Treatment Seeking Population | 76 | 1 |
| Diagnosed Population | 77 | 1 |
| Prescription Population | 78 | 1 |
| Geographical Segmentation | 79 | 2 |
| Drivers and Restraints for the Migraine Market | 81 | 1 |
| Drivers | 82 | 1 |
| The Increasing Awareness will Result in an Increasing Prescription Rate | 82 | 1 |
| Restraints | 82 | 1 |
| Low Treatment Seeking Behavior and Diagnosis Rate Restrain the Growth in Prescription Population | 82 | 1 |
| Falling Prices of Migraine Treatment will Restrain the Market by Offsetting the Impact of Increasing Volume | 82 | 1 |
| Alternative Medicine and Self-Care Techniques will Restrict the Market for Migraine Pain Medications | 82 | 1 |
| Pain Management Therapeutics Market for Cancer Pain | 82 | 1 |
| Introduction | 82 | 1 |
| The Cancer Pain Drug Market is Fuelled by Opioids | 83 | 1 |
| Revenue | 83 | 2 |
| Branded Vs Generic Share | 85 | 1 |
| Annual Cost of Therapy | 86 | 1 |
| Treatment Flow Algorithm | 87 | 1 |
| Treatment Usage Patterns | 88 | 2 |
| Diseased Population | 90 | 1 |
| Treatment Seeking Population | 91 | 1 |
| Diagnosed Population | 92 | 1 |
| Prescription Population | 92 | 4 |
| Geographical Segmentation | 96 | 2 |
| Drivers and Restraints for the Cancer Pain Market | 98 | 1 |
| Drivers | 99 | 1 |
| Rising Incidence of Cancer Drives the Market | 99 | 1 |
| New Modes of Delivery Will Help in Better Management of Pain for a Longer Duration | 99 | 1 |
| Unmet Need Due to Lack of Novel Modes of Action | 99 | 1 |
| Restraints | 99 | 1 |
| Concerns over the Risks of Addiction Related to Drug Therapy Affect the Prescription Rate | 99 | 1 |
| Patients Fear that Treatment for Pain will Interfere with Their Cancer Treatment | 99 | 1 |
| Excessive State Regulation of Analgesics | 100 | 1 |
| Pain Management Therapeutics Market for Osteoarthritis Pain | 100 | 1 |
| Introduction | 100 | 1 |
| Revenue | 101 | 1 |
| Branded vs. Generic Share | 102 | 1 |
| Annual Cost of Therapy | 103 | 1 |
| Treatment Flow Algorithm | 104 | 1 |
| Treatment Usage Patterns | 105 | 1 |
| Diseased Population | 106 | 1 |
| Treatment Seeking Population | 107 | 1 |
| Diagnosed Population | 108 | 1 |
| Prescription Population | 108 | 2 |
| Geographical Segmentation | 110 | 2 |
| Drivers and Restraints for the Osteoarthritis Pain Market | 112 | 1 |
| Drivers | 113 | 1 |
| Rising Prevalence | 113 | 1 |
| Rapid Increase of the Obesity Population | 113 | 1 |
| Lifestyle Changes Increase the Incidence of Osteoarthritis | 113 | 1 |
| Restraints | 113 | 1 |
| Pain Management Therapeutics are Associated with Several Side Effects | 113 | 1 |
| Low Treatment Seeking and Diagnosis Rates | 113 | 1 |
| Pain Management Therapeutics Market for Rheumatoid Arthritis Pain | 114 | 1 |
| Introduction | 114 | 1 |
| Revenue | 114 | 2 |
| Branded vs. Generic Share | 116 | 1 |
| Annual Cost of Therapy | 117 | 1 |
| Treatment Flow Algorithm | 118 | 1 |
| Treatment Usage Patterns | 119 | 1 |
| Diseased Population | 120 | 1 |
| Treatment Seeking Population | 121 | 1 |
| Diagnosed Population | 122 | 1 |
| Prescription Population | 123 | 1 |
| Geographical Segmentation | 124 | 2 |
| Drivers and Restraints for the Rheumatoid Arthritis Market | 126 | 1 |
| Drivers | 127 | 1 |
| Improvement in Awareness and Resultant Diagnoses Will Drive the Market | 127 | 1 |
| Restraints | 127 | 1 |
| Inadequate Awareness of Pain Management | 127 | 1 |
| Adverse Effects | 127 | 1 |
| Pain Management Therapeutics Market for Low Back Pain | 127 | 1 |
| Introduction | 127 | 1 |
| Revenue | 128 | 1 |
| Branded vs. Generic Share | 129 | 1 |
| Annual Cost of Therapy | 130 | 1 |
| Treatment Flow Algorithm | 131 | 1 |
| Treatment Usage Patterns | 132 | 2 |
| Diseased Population | 134 | 1 |
| Treatment Seeking Population | 135 | 1 |
| Diagnosed Population | 136 | 1 |
| Prescription Population | 137 | 1 |
| Geographical Segmentation | 138 | 2 |
| Drivers and Restraints for the Low Back Pain Market | 140 | 1 |
| Drivers | 141 | 1 |
| Rising Elderly Population Will Drive the Market | 141 | 1 |
| Sedentary Lifestyle Increases LBP | 141 | 1 |
| Restraints | 141 | 1 |
| Low Treatment Seeking Rate and Low Prescription Rate Restricts the Market | 141 | 1 |
| Pain Management Therapeutics Market for Post-Operative Pain | 141 | 1 |
| Introduction | 141 | 2 |
| Revenue | 143 | 1 |
| Branded vs. Generic Share | 144 | 1 |
| Annual Cost of Therapy | 145 | 1 |
| Treatment Flow Algorithm | 146 | 1 |
| Treatment Usage Patterns | 147 | 1 |
| Diseased Population | 148 | 1 |
| Treatment Seeking Population | 149 | 1 |
| Diagnosed Population | 150 | 1 |
| Prescription Population | 150 | 2 |
| Geographical Segmentation | 152 | 2 |
| Drivers and Restraints for the Post-Operative Pain Market | 154 | 1 |
| Drivers | 155 | 1 |
| Substantial Unmet Need Increases Market Potential | 155 | 1 |
| Titration of Pain Management Medications is Convenient in a Surgical Facility | 155 | 1 |
| Restraints | 155 | 1 |
| Expansion of Minimally Invasive Surgical Procedures | 155 | 1 |
| Peri-Operative Side Effects | 155 | 1 |
| Pain Management Therapeutics Market - Geographical Landscape | 156 | 27 |
| The US | 159 | 1 |
| Revenue | 159 | 2 |
| Annual Cost of Therapy | 161 | 1 |
| Treatment Usage Patterns | 162 | 2 |
| Diseased Population | 164 | 1 |
| Treatment Seeking Population | 165 | 1 |
| Diagnosed Population | 166 | 1 |
| Prescription Population | 167 | 1 |
| Top Five Countries in Europe | 168 | 1 |
| Revenue | 168 | 1 |
| Annual Cost of Therapy | 169 | 1 |
| Treatment Usage Patterns | 170 | 2 |
| Diseased Population | 172 | 1 |
| Treatment Seeking Population | 173 | 1 |
| Diagnosed Population | 174 | 1 |
| Prescription Population | 175 | 1 |
| Japan | 176 | 1 |
| Revenue | 176 | 1 |
| Annual Cost of Therapy | 177 | 1 |
| Treatment Usage Patterns | 178 | 1 |
| Diseased Population | 179 | 1 |
| Treatment Seeking Population | 180 | 1 |
| Diagnosed Population | 181 | 1 |
| Prescription Population | 182 | 1 |
| Pain Management Therapeutics Market - Pipeline Analysis | 183 | 25 |
| Introduction | 183 | 2 |
| Research and Development Pipeline Fibromyalgia | 185 | 2 |
| Research and Development Pipeline Neuropathic Pain | 187 | 6 |
| Research and Development Pipeline Migraine | 193 | 3 |
| Research and Development Pipeline Cancer Pain | 196 | 2 |
| Research and Development Pipeline Osteoarthritis Pain | 198 | 2 |
| Research and Development Pipeline Low Back Pain | 200 | 2 |
| Research and Development Pipeline Post-Operative Pain | 202 | 2 |
| Profiles of Key Late-Stage Drugs in the Pain Management Therapeutics Market | 204 | 1 |
| Vimpat (Lacosamide) | 204 | 1 |
| Overview | 204 | 1 |
| Mechanism of Action | 204 | 1 |
| Droxidopa | 205 | 1 |
| Mechanism of Action | 205 | 1 |